Shots:
- Keytruda, Dupixent, and Skyrizi emerged as the leading monoclonal antibody products in 2025, generating revenues of $31.68B, $18.48B, and $17.56B, respectively. Strong demand across approved indications, broader patient adoption, market share gains, and expansion into new treatment areas supported growth among the leading products
- The global monoclonal antibodies market was valued at $267.6B in 2025 and is projected to grow from $294.1B in 2026 to $547.3B by 2033, at a 9.3% CAGR from 2026 to 2033. North America accounted for the largest market share, exceeding 41.0% in 2025, while the rising prevalence of cancer, cardiovascular diseases, and autoimmune disorders continues to fuel demand for biologics and monoclonal antibody therapies
- The report ranks the Top 20 Monoclonal Antibody Products of 2026 based on product revenues reported for fiscal year 2025, with revenues converted to USD. It highlights each product’s approved indications, mechanism of action, year-over-year revenue performance, factors driving growth or decline, and the latest regulatory approvals, clinical developments, formulation launches, and other updates shaping the global monoclonal antibody market
20. Proprietary Name: Taltz
Non-Proprietary Name: Ixekizumab
Company: Eli Lilly
First Approved: US (Mar 22, 2016), EU (Apr 25, 2016)
Total Revenue: $3.56B
- Taltz (ixekizumab) is a humanized monoclonal antibody targeting IL-17A and is approved across four indications, including Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis
- Taltz selectively binds to IL-17A and blocks its interaction with the IL-17 receptor, helping reduce inflammation associated with psoriasis and other chronic inflammatory joint diseases
- In 2025, Taltz’s sales increased to $3.56B from $3.26B in 2024, up 9.2% YoY, driven by increased sales in both the US and international markets. In Aug 2026, Eli Lilly reported Phase IIIB TOGETHER-PSO results for Taltz + Zepbound in adults with psoriasis and obesity or overweight
19. Proprietary Name: Perjeta
Non-Proprietary Name: Pertuzumab
Company: Roche
First Approved: US (Jun 08, 2012), EU (Mar 04, 2013)
Total Revenue: $3.75B
- Perjeta (pertuzumab) is a humanized monoclonal antibody targeting HER2 and is approved for HER2-Positive Breast Cancer, including HER2-positive metastatic breast cancer and early-stage disease in combination with trastuzumab and chemotherapy
- Perjeta binds to a different region of the HER2 receptor than trastuzumab, preventing HER2 from pairing with other HER-family receptors and helping inhibit tumor-cell growth and survival
- In 2025, Perjeta’s sales declined to $3.75B from $4.0B in 2024, down 6.3% YoY, primarily due to the continued conversion of patients to Phesgo
18. Proprietary Name: Prolia
Non-Proprietary Name: Denosumab
Company: Amgen
First Approved: US (Jun 01, 2010), EU (May 26, 2010)
Total Revenue: $4.41B
- Prolia (denosumab) is a human monoclonal antibody targeting RANKL and is approved for Postmenopausal Osteoporosis, Glucocorticoid-Induced Osteoporosis, and to increase bone mass in patients receiving certain cancer therapies, including women with breast cancer receiving adjuvant aromatase inhibitor therapy
- Prolia binds to RANKL and blocks its interaction with RANK, reducing osteoclast formation and activity and thereby slowing bone resorption and helping increase bone mass
- In 2025, Prolia’s sales increased to $4.41B from $4.37B in 2024, up 0.9% YoY, primarily driven by 2% volume growth and favorable changes in estimated sales deductions, partly offset by lower net selling price
17. Proprietary Name: Kesimpta
Non-Proprietary Name: Ofatumumab
Company: Novartis
First Approved: US (2009), EU (Mar 26, 2021)
Total Revenue: $4.42B
- Kesimpta (ofatumumab) is a fully human monoclonal antibody targeting CD20 and is approved for relapsing forms of Multiple Sclerosis (RMS) in adults, including Clinically Isolated Syndrome (CIS), Relapsing-Remitting Multiple Sclerosis (RRMS), and Active Secondary Progressive Multiple Sclerosis (SPMS)
- Kesimpta binds to CD20 on B cells, leading to B-cell depletion and reducing the immune activity that contributes to inflammation and damage in the central nervous system associated with multiple sclerosis
- In 2025, Kesimpta’s sales increased to $4.42B from $3.22B in 2024, up 37.3% YoY, driven by increased demand and strong market access across regions, supported by its high efficacy, B-cell targeting, and convenient at-home self-administration
16. Proprietary Name: Humira
Non-Proprietary Name: Adalimumab
Company: AbbVie
First Approved: US (Dec 31, 2002), EU (Sep 8, 2003)
Total Revenue: $4.54B
- Humira (adalimumab) is a recombinant human monoclonal antibody targeting tumor necrosis factor (TNF)-α and is approved across nine indications, including Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis
- Humira binds to TNF-α and blocks its interaction with TNF receptors, helping suppress the inflammatory response involved in several autoimmune and chronic inflammatory diseases
- In 2025, Humira’s sales declined to $4.54B from $8.99B in 2024, down 49.5% YoY, primarily due to the continued impact of direct biosimilar competition following the loss of exclusivity
15. Proprietary Name: Ultomiris
Non-Proprietary Name: Ravulizumab
Company: AstraZeneca
First Approved: US (Dec 21, 2018), EU (Jul 02, 2019)
Total Revenue: $4.71B
- Ultomiris (ravulizumab) is a long-acting monoclonal antibody targeting complement protein C5 and is approved for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
- Ultomiris binds to complement component C5 and prevents its cleavage into C5a and C5b, thereby inhibiting terminal complement activation and reducing complement-mediated destruction of red blood cells
- In 2025, Ultomiris’ sales increased to $4.71B from $3.92B in 2024, up 20.2% YoY, driven by increasing patient demand and continued conversion from Soliris
14. Proprietary Name: Tremfya
Non-Proprietary Name: Guselkumab
Company: Janssen Pharmaceuticals
First Approved: US (Jul 13, 2017), EU (Nov 10, 2017)
Total Revenue: $5.15B
- Tremfya (guselkumab) is a human monoclonal antibody that selectively targets the IL-23 p19 subunit and is approved for Moderate-to-Severe Plaque Psoriasis and Active Psoriatic Arthritis
- Tremfya selectively binds to IL-23 and inhibits its interaction with the IL-23 receptor, helping reduce the inflammatory signaling that contributes to psoriasis and psoriatic arthritis
- In 2025, Tremfya’s sales increased to $5.15B from $3.67B in 2024, up 40.3% YoY, driven by continued market share gains and overall market growth
13. Proprietary Name: Vabysmo
Non-Proprietary Name: Faricimab-svoa
Company: Roche
First Approved: US (28 Jan, 2022), EU (15 Sep, 2022)
Total Revenue: $5.19B
- Vabysmo (faricimab-svoa) is a bispecific monoclonal antibody targeting VEGF-A and Angiopoietin-2 (Ang-2), and is approved for three retinal conditions, including Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema Following Retinal Vein Occlusion (RVO)
- Vabysmo simultaneously blocks VEGF-A and Ang-2, helping reduce abnormal blood vessel growth and vascular leakage while improving retinal stability in patients with retinal diseases
- In 2025, Vabysmo’s sales increased to $5.19B from $4.27B in 2024, up 21.5% YoY, driven by sales growth across Europe, Japan, and other international markets
12. Proprietary Name: Xolair
Non-Proprietary Name: Omalizumab
Company: Roche & Novartis
First Approved: US (Jun 20, 2003), EU (Oct 25, 2005)
Total Revenue: $5.61B
- Xolair (omalizumab) is a recombinant humanized monoclonal antibody targeting immunoglobulin E (IgE) and is approved across four indications, including Asthma, Chronic Rhinosinusitis with Nasal Polyps, Chronic Spontaneous Urticaria, and IgE-Mediated Food Allergy
- Xolair binds to free IgE and prevents it from binding to high-affinity IgE receptors, helping reduce allergic inflammation and the release of inflammatory mediators involved in allergic diseases
- In 2025, Xolair’s sales increased to $5.61B from $4.37B in 2024, up 28.4% YoY, driven by higher US sales, strong uptake in food allergy, and continued growth of the Chronic Spontaneous Urticaria indication, particularly in emerging markets
11. Proprietary Name: Hemlibra
Non-Proprietary Name: Emicizumab
Company: Roche
First Approved: US (Nov 16, 2017), EU (Feb 23, 2018)
Total Revenue: $6.01B
- Hemlibra (emicizumab) is a humanized bispecific monoclonal antibody approved for the treatment of Hemophilia A with congenital Factor VIII deficiency, including patients with and without Factor VIII inhibitors
- Hemlibra bridges activated Factor IX and Factor X to restore the function of missing activated Factor VIII, helping the blood-clotting process and reducing bleeding episodes in people with Hemophilia A
- In 2025, Hemlibra’s sales increased to $6.01B from $4.98B in 2024, up 20.7% YoY, driven by growing adoption as a standard of care, with US sales rising 6% and international growth supported by expanded access and patients switching from existing treatments
10. Proprietary Name: Imfinzi
Non-Proprietary Name: Durvalumab
Company: AstraZeneca
First Approved: US (May 01, 2017), EU (Sep 21, 2018)
Total Revenue: $6.06B
- Imfinzi (durvalumab) is a human monoclonal antibody targeting PD-L1 and is approved across multiple cancer indications, including Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Locally Advanced or Metastatic Biliary Tract Cancer, and Unresectable Hepatocellular Carcinoma
- Imfinzi blocks the interaction of PD-L1 with PD-1 and CD80, helping restore T-cell activity and strengthen the immune response against cancer cells
- In 2025, Imfinzi’s sales increased to $6.06B from $4.71B in 2024, up 28.7% YoY, supported by continued demand across its approved cancer indications and broader adoption in lung and other solid tumors. In May 2026, the US FDA approved Imfinzi in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer
9. Proprietary Name: Stelara
Non-Proprietary Name: Ustekinumab
Company: Janssen Pharmaceutical
First Approved: US (Sep 25, 2009), EU (Jan 15, 2009)
Total Revenue: $6.07B
- Stelara (ustekinumab) is a human monoclonal antibody targeting the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), and is approved across four indications, including Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis
- Stelara binds to the p40 subunit of IL-12 and IL-23, blocking their interaction with the IL-12Rβ1 receptor and reducing inflammatory signaling involved in immune-mediated diseases
- In 2025, Stelara’s sales declined to $6.07B from $10.36B in 2024, down 41.4% YoY, primarily due to biosimilar competition following the loss of exclusivity in the US and other markets. In May 2026, the US FDA approved Stelara for pediatric patients aged 2 years and older with moderately to severely active Crohn’s disease
8. Proprietary Name: Entyvio
Non-Proprietary Name: Vedolizumab
Company: Takeda
First Approved: US (May 20, 2014), EU (May 22, 2014)
Total Revenue: $6.14B
- Entyvio (vedolizumab) is a humanized monoclonal antibody that selectively targets the α4β7 integrin and is approved for Ulcerative Colitis and Crohn’s Disease in patients who have had an inadequate response or intolerance to conventional therapies or biologics
- Entyvio selectively binds to the α4β7 integrin on certain immune cells, blocking their interaction with MAdCAM-1 and reducing the migration of these cells into inflamed gastrointestinal tissue
- In 2025, Entyvio’s sales increased to $6.14B from $5.59B in 2024, up 9.8% YoY. In Feb 2026, Takeda reported positive Phase III KEPLER results for Entyvio in children and adolescents with moderate-to-severe Ulcerative Colitis, with nearly half achieving clinical remission at Week 54
7. Proprietary Name: Cosentyx
Non-Proprietary Name: Secukinumab
Company: Novartis
First Approved: US (Jan 21, 2015), EU (Jan 14, 2015)
Total Revenue: $6.66B
- Cosentyx (secukinumab) is a human monoclonal antibody that selectively targets IL-17A and is approved across multiple inflammatory conditions, including Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis, and Hidradenitis Suppurativa
- Cosentyx binds to IL-17A and blocks its interaction with the IL-17 receptor, helping reduce the inflammatory response involved in several chronic immune-mediated diseases
- In 2025, Cosentyx’s sales increased to $6.66B from $6.14B in 2024, up 8.5% YoY, driven by demand from recent launches, including the Hidradenitis Suppurativa indication and US IV formulation, along with volume growth across core indications. In Jul 2026, Novartis reported the US FDA approval of Cosentyx for pediatric patients with Hidradenitis Suppurativa
6. Proprietary Name: Ocrevus
Non-Proprietary Name: Ocrelizumab
Company: Roche
First Approved: US (Mar 28, 2017), EU (Jan 08, 2018)
Total Revenue: $8.87B
- Ocrevus (ocrelizumab) is a humanized monoclonal antibody targeting CD20 and is approved for Multiple Sclerosis, including relapsing forms such as clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease, and primary progressive multiple sclerosis
- Ocrevus binds to CD20 on B cells, leading to their depletion and reducing the immune activity that contributes to inflammation and damage in the central nervous system associated with multiple sclerosis
- In 2025, Ocrevus’ sales increased to $8.87B from $7.46B in 2024, up 18.9% YoY, driven by strong uptake of the subcutaneous formulation. In Jul 2026, Roche reported that Ocrevus remained one of its top growth drivers, supported by continued strong demand across global markets
5. Proprietary Name: Opdivo
Non-Proprietary Name: Nivolumab
Company: Bristol-Myers Squibb
First Approved: US (Mar 4, 2015), EU (Jun 19, 2015)
Total Revenue: $10.28B
- Opdivo (nivolumab) is a human PD-1 blocking monoclonal antibody approved across multiple cancer indications, including Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, and Head and Neck Squamous Cell Carcinoma
- Opdivo blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, helping restore T-cell activity and enabling the immune system to recognize and attack cancer cells
- In 2025, Opdivo’s sales increased to $10.28B from $9.3B in 2024, up 10.5% YoY, primarily driven by strong demand for combination cancer therapies, increased patient adoption, and continued momentum across global markets. In Aug 2026, the FDA granted accelerated approval to Tudriqev + Opdivo for adults with unresectable advanced cutaneous melanoma that progressed after an anti-PD-1-based regimen
4. Proprietary Name: Darzalex
Non-Proprietary Name: Daratumumab
Company: Janssen Pharmaceuticals
First Approved: US (Nov 16, 2015), EU (May 20, 2016)
Total Revenue: $14.35B
- Darzalex (daratumumab) is a human monoclonal antibody targeting CD38 and is primarily approved for the treatment of Multiple Myeloma, including use in combination with other therapies across different treatment settings
- Darzalex binds to CD38, a protein highly expressed on multiple myeloma cells, helping eliminate cancer cells through multiple immune-mediated mechanisms, including complement-dependent and antibody-dependent cellular cytotoxicity
- In 2025, Darzalex’s sales increased to $14.35B from $11.67B in 2024, up 23.0% YoY, driven by continued market share gains and overall market growth. In Jul 2026, Johnson & Johnson reported the US FDA approval of Tecvayli in combination with Darzalex Faspro for patients with relapsed or refractory multiple myeloma
3. Proprietary Name: Skyrizi
Non-Proprietary Name: Risankizumab
Company: AbbVie
First Approved: US (Apr 23, 2019), EU (Apr 26, 2019)
Total Revenue: $17.56B
- Skyrizi (risankizumab) is a humanized monoclonal antibody that selectively targets the IL-23 p19 subunit and is approved across four indications, including Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis
- Skyrizi selectively binds to the p19 subunit of IL-23, blocking IL-23 signaling and helping regulate the inflammatory pathways involved in chronic immune-mediated diseases
- In 2025, Skyrizi’s sales increased to $17.56B from $11.71B in 2024, up 50.0% YoY, primarily driven by continued strong market share uptake and market growth across all approved indications. In Jun 2026, the US FDA approved Skyrizi for pediatric patients aged 6 years and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis
2. Proprietary Name: Dupixent
Non-Proprietary Name: Dupilumab
Company: Sanofi and Regeneron
First Approved: US (Mar 28, 2017), EU (Sep 26, 2017)
Total Revenue: $18.48B
- Dupixent is a fully human monoclonal antibody targeting the IL-4 receptor alpha subunit, blocking IL-4 and IL-13 signaling, and is approved across eight indications, including Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis, Chronic Spontaneous Urticaria, Chronic Obstructive Pulmonary Disease, and Bullous Pemphigoid
- Dupixent blocks signaling from the cytokines IL-4 and IL-13, two key drivers of type 2 inflammation, helping reduce inflammatory responses associated with several allergic and immune-mediated diseases
- In 2025, Dupixent’s sales increased to $18.48B from $13.61B in 2024, up 35.8% YoY, driven by continuing strong demand across its approved indications. In Apr 2026, the US FDA approved Dupixent for Chronic Spontaneous Urticaria (CSU) in patients aged 2–11 years who remain symptomatic despite H1 antihistamine treatment
1. Proprietary Name: Keytruda
Non-Proprietary Name: Pembrolizumab
Company: Merck & Co.
First Approved: US (Sep 04, 2014), EU (Jul 17, 2015)
Total Revenue: $31.68B
- Keytruda is a human PD-1 blocking antibody approved across 20 indications, including Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Biliary Tract Cancer, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma, Tumor Mutational Burden-High Cancer, Cutaneous Squamous Cell Carcinoma, and Triple-Negative Breast Cancer
- Keytruda blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, activating T-lymphocytes that can target tumour cells but may also affect healthy cells
- In 2025, Keytruda’s sales increased to $31.68B from $29.48B in 2024, up 7.5% YoY, driven by higher demand and net pricing in the US, increased use across earlier-stage and metastatic indications, and stronger international uptake. In Aug 2026, Merck and Moderna reported positive Phase III results for intismeran autogene plus Keytruda in resected high-risk melanoma
Criteria:
- The report is based on monoclonal antibody product revenues reported during fiscal year 2025, covering leading therapeutic antibodies across oncology, immunology, ophthalmology, hematology, and other major therapeutic areas to provide a comprehensive ranking of the world’s leading monoclonal antibody products
- For products with non-December fiscal year endings, revenue has been aligned to the January–December 2025 period using quarterly and annual financial filings. Where product-specific revenues were not separately disclosed, the relevant product, franchise, or therapeutic-area figures were used based on the company’s reported business structure and publicly available financial disclosures
- Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025 to ensure consistency and comparability across all products in the ranking
Related Post: Top 20 Monoclonal Antibodies of 2025